336 related articles for article (PubMed ID: 25463517)
1. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Wang S; Zhang XQ; Song CG; Xiao T; Zhao M; Zhu G; Zhao CS
Neuroscience; 2015 Feb; 286():203-15. PubMed ID: 25463517
[TBL] [Abstract][Full Text] [Related]
2. Bumetanide reduce the seizure susceptibility induced by pentylenetetrazol via inhibition of aberrant hippocampal neurogenesis in neonatal rats after hypoxia-ischemia.
Hu JJ; Yang XL; Luo WD; Han S; Yin J; Liu WH; He XH; Peng BW
Brain Res Bull; 2017 Apr; 130():188-199. PubMed ID: 28161194
[TBL] [Abstract][Full Text] [Related]
3. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
Cleary RT; Sun H; Huynh T; Manning SM; Li Y; Rotenberg A; Talos DM; Kahle KT; Jackson M; Rakhade SN; Berry G; Jensen FE
PLoS One; 2013; 8(3):e57148. PubMed ID: 23536761
[TBL] [Abstract][Full Text] [Related]
4. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
Kahle KT; Staley KJ
Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
[TBL] [Abstract][Full Text] [Related]
5. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
6. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1.
Kahle KT; Barnett SM; Sassower KC; Staley KJ
J Child Neurol; 2009 May; 24(5):572-6. PubMed ID: 19406757
[TBL] [Abstract][Full Text] [Related]
7. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Welzel B; Schmidt R; Kirchhoff L; Gramer M; Löscher W
Epilepsy Behav; 2023 Feb; 139():109057. PubMed ID: 36586153
[TBL] [Abstract][Full Text] [Related]
8. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Johne M; Käufer C; Römermann K; Gailus B; Gericke B; Löscher W
Epilepsia; 2021 Jun; 62(6):1460-1471. PubMed ID: 33955541
[TBL] [Abstract][Full Text] [Related]
9. NKCC1 transporter facilitates seizures in the developing brain.
Dzhala VI; Talos DM; Sdrulla DA; Brumback AC; Mathews GC; Benke TA; Delpire E; Jensen FE; Staley KJ
Nat Med; 2005 Nov; 11(11):1205-13. PubMed ID: 16227993
[TBL] [Abstract][Full Text] [Related]
10. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
11. CNS pharmacology of NKCC1 inhibitors.
Löscher W; Kaila K
Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
[TBL] [Abstract][Full Text] [Related]
12. Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Welzel B; Johne M; Löscher W
Epilepsy Behav; 2023 May; 142():109189. PubMed ID: 37037061
[TBL] [Abstract][Full Text] [Related]
13. Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.
Kaila K; Löscher W
Epilepsia; 2022 Jul; 63(7):1868-1873. PubMed ID: 35524446
[TBL] [Abstract][Full Text] [Related]
14. Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus.
Nardou R; Ben-Ari Y; Khalilov I
J Neurophysiol; 2009 Jun; 101(6):2878-88. PubMed ID: 19297515
[TBL] [Abstract][Full Text] [Related]
15. Depolarizing γ-aminobutyric acid contributes to glutamatergic network rewiring in epilepsy.
Kourdougli N; Pellegrino C; Renko JM; Khirug S; Chazal G; Kukko-Lukjanov TK; Lauri SE; Gaiarsa JL; Zhou L; Peret A; Castrén E; Tuominen RK; Crépel V; Rivera C
Ann Neurol; 2017 Feb; 81(2):251-265. PubMed ID: 28074534
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous brain distribution of bumetanide following systemic administration in rats.
Löscher W; Gramer M; Römermann K
Biopharm Drug Dispos; 2024 Jun; 45(3):138-148. PubMed ID: 38823029
[TBL] [Abstract][Full Text] [Related]
17. Chloride cotransporter NKCC1 inhibitor bumetanide protects against white matter injury in a rodent model of periventricular leukomalacia.
Jantzie LL; Hu MY; Park HK; Jackson MC; Yu J; Maxwell JR; Jensen FE
Pediatr Res; 2015 Apr; 77(4):554-62. PubMed ID: 25585037
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Na
Zhang J; Pu H; Zhang H; Wei Z; Jiang X; Xu M; Zhang L; Zhang W; Liu J; Meng H; Stetler RA; Sun D; Chen J; Gao Y; Chen L
Neurochem Int; 2017 Dec; 111():23-31. PubMed ID: 28577991
[TBL] [Abstract][Full Text] [Related]
19. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.
Töllner K; Brandt C; Römermann K; Löscher W
Eur J Pharmacol; 2015 Jan; 746():167-73. PubMed ID: 25449033
[TBL] [Abstract][Full Text] [Related]
20. Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Johne M; Römermann K; Hampel P; Gailus B; Theilmann W; Ala-Kurikka T; Kaila K; Löscher W
Epilepsia; 2021 Apr; 62(4):920-934. PubMed ID: 33258158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
